Partners Capital Investment Group, LLP Acadia Pharmaceuticals Inc Transaction History

Partners Capital Investment Group, LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$14.2 - $18.63 $43,679 - $57,305	-3,076 Reduced 7.43%	38,318 $610,000
Q3 2022 Nov 14, 2022	SELL	$14.11 - $18.27 $1.47 Million - $1.9 Million	-103,895 Reduced 71.51%	41,394 $677,000
Q1 2022 May 16, 2022	SELL	$20.94 - $27.5 $1.67 Million - $2.19 Million	-79,541 Reduced 35.38%	145,289 $3.52 Million
Q4 2021 Feb 14, 2022	BUY	$16.79 - $27.09 $294,597 - $475,321	17,546 Added 8.46%	224,830 $5.25 Million
Q3 2021 Nov 15, 2021	BUY	$15.78 - $24.77 $1.35 Million - $2.12 Million	85,482 Added 70.18%	207,284 $3.44 Million
Q2 2021 Aug 16, 2021	BUY	$19.4 - $27.42 $673,005 - $951,227	34,691 Added 39.82%	121,802 $2.97 Million
Q1 2021 May 17, 2021	BUY	$25.02 - $54.99 $1.18 Million - $2.6 Million	47,288 Added 118.75%	87,111 $2.25 Million
Q4 2020 Feb 16, 2021	BUY	$41.04 - $56.79 $1.63 Million - $2.26 Million	39,823 New	39,823 $2.13 Million

279

156M

901K

314K

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.76B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

Get notified when there are updates to the investment portfolio of Partners Capital Investment Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Partners Capital Investment Group, LLP with notifications on news.